VBI Vaccines has announced a collaboration with GlaxoSmithKline (GSK) to clinically evaluate the combination of VBI-1901, VBI’s cancer vaccine immunotherapeutic, with GSK’s proprietary AS01B adjuvant system.
Roche announced that its lung cancer drug Tecentriq (atezolizumab) has significantly improved overall survival (OS) rate in the phase III IMpower110 study.
Merck announced the initiation of two global pivotal Phase III trials (EVOLUTION RMS 1 and 2) studying the efficacy and safety of evobrutinib, an oral, highly selective Bruton’s Tyrosine Kinase (BTK) inhibitor in adult patients with relapsing multiple sclerosis (RMS).
Janssen Pharmaceutical said that the esketamine nasal spray along with the comprehensive standard of care (SOC) has met the primary efficacy endpoints of two phase 3 trials featuring adult patients with a major depressive disorder.
AstraZeneca announced that its Imfinzi (durvalumab) has significantly improved overall survival (OS) in patients with previously-untreated extensive-stage small cell lung cancer (SCLC) in the phase III Caspian study.
Novartis announced today results from two new clinical trials evaluating improvement in heart structure and function and long-term safety of Entresto (sacubitril/valsartan) in patients with heart failure with reduced ejection fraction (HFrEF).
VALBIOTIS has announced additional positive results from its Phase IIA clinical study of VALEDIA on four parameters which were among the secondary endpoints of the study: blood triglyceride levels, Fatty Liver Index, (fat accumulation in the liver), blood LDL cholesterol levels, and arterial hypertension.
Roche’s one-dose Xofluza (baloxavir marboxil) has achieved primary endpoint in phase III MINISTONE-2 study of children with flu.
Novartis said that its human anti-CD20 monoclonal antibody ofatumumab (OMB157) showed superiority over Aubagio (teriflunomide) in two phase 3 trials in patients with relapsing forms of multiple sclerosis (RMS).
AstraZeneca’s new medicine anifrolumab has achieved primary endpoint in the phase III Tulip 2 trial of systemic lupus erythematosus (SLE).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.